title: HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.
abstract: OBJECTIVE
  The efficacy of trastuzumab in Chinese breast cancer (BC) patients has rarely been reported. This study was designed to compare the clinical outcomes of HER2-positive BC patients receiving or not receiving trastuzumab treatment and HER2-negative BC patients.
  
  
  METHODS
  This study involved three groups of patients. The first group was 115 human epidermal growth factor receptor 2 (HER2)-positive BC patients treated with trastuzumab who were enrolled at Sun Yat-sen University Cancer Center between January 2002 and July 2010; the second group was a matched control group of 115 HER2-positive patients who did not receive trastuzumab treatment; the third group was a matched group of 115 HER2-negative patients who received conventional therapy in the adjuvant setting. The primary endpoint was 3-year and 5-year disease-free survival (3-DFS and 5-DFS, respectively). The Kaplan-Meier method, log-rank test, and multivariate Cox proportional hazard regression model were used for survival analysis. The differences in survival rates among the three groups were also analyzed according to two different periods: 2002-2006 and 2007-2010.
  
  
  RESULTS
  The median duration of follow-up was 36 months (range, 12-111 months). The 3-DFS rates in the HER2-negative group, the HER2-positive group who received trastuzumab treatment, and the HER2-positive group who did not receive trastuzumab treatment were 82.6%, 89.6%, and 67.0%, respectively. The 3-DFS rate for the total study population was statistically significant (P < 0.001). Further analysis indicated a statistically significant difference in 3-DFS between either of the first two groups and the third group (P < 0.01), but the difference between the first two groups was not statistically significant (P = 0.157). Among the three groups, the 3-DFS rates during 2002-2006 did not have a significant difference compared with that during 2007-2010.
  
  
  CONCLUSIONS
  This study has further confirmed the efficacy of trastuzumab for HER2-positive operable BC in Chinese patients. It has also demonstrated that the 3-DFS and 5-DFS rates between HER2-positive patients receiving trastuzumab treatment and HER2-negative patients are comparable.
authors: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
authors: Tao
authors: T
authors: Qin
authors: Zhongyu
authors: Z
authors: Yuan
authors: Roujun
authors: R
authors: Peng
authors: Bing
authors: B
authors: Bai
authors: Yanxia
authors: Y
authors: Shi
authors: Xiaoyu
authors: X
authors: Teng
authors: Donggeng
authors: D
authors: Liu
authors: Shusen
authors: S
authors: Wang
keywords: HER2; adjuvant treatment; breast cancer; survival analysis; trastuzumab
references: Ann Oncol. 2006 Mar;17(3):409-14
references: 16332965
references: Lancet. 2012 Feb 4;379(9814):432-44
references: 22152853
references: Lancet Oncol. 2011 Mar;12(3):236-44
references: 21354370
references: Int J Cancer. 2012 Dec 1;131(11):2622-31
references: 22377956
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: J Clin Invest. 2011 Oct;121(10):3797-803
references: 21965336
references: Lancet. 2009 Apr 25;373(9673):1463-79
references: 19394537
references: J Clin Oncol. 2010 Jan 1;28(1):92-8
references: 19933921
references: Value Health. 2009 Nov-Dec;12 Suppl 3:S82-4
references: 20586989
references: Med Res Rev. 2012 Jan;32(1):166-215
references: 22183797
references: Cancer. 2010 Jun 15;116(12):2856-67
references: 20564392
references: Ann Oncol. 2009 Aug;20(8):1319-29
references: 19535820
references: J Clin Oncol. 2011 Sep 1;29(25):3366-73
references: 21768458
references: N Engl J Med. 2011 Oct 6;365(14):1273-83
references: 21991949
references: J Clin Oncol. 2005 Jun 1;23(16):3676-85
references: 15738535
references: Breast Cancer Res Treat. 2011 Nov;130(2):489-98
references: 21837481
references: J Clin Oncol. 2007 Jan 1;25(1):118-45
references: 17159189
references: Lancet. 2010 Jan 30;375(9712):377-84
references: 20113825
references: Oncologist. 2009 Apr;14(4):320-68
references: 19346299
references: J Clin Oncol. 2010 Apr 20;28(12):2024-31
references: 20308670
references: Ann Surg Oncol. 2011 Oct;18(11):3072-8
references: 21847700